Inside Peptides
Search
Menu

FDA safety concerns for compounded BPC-157

Regulatory Notice 3 min read
Reporting Source: U.S. Food and Drug Administration

Source checked · External scientific review not documented

Research Summary

FDA identifies potential safety risks for compounded BPC-157 and insufficient information to determine whether it would cause harm by the proposed routes of administration.

Key Findings & Takeaways
  • FDA identifies potential immunogenicity concerns for certain administration routes.
  • Peptide-related impurities and API characterization complicate safety assessment.
  • A lack of adequate safety information is not evidence of safety.
  • Approval, compounding eligibility, and anti-doping status are separate questions.

The FDA safety resource identifies concerns about compounded BPC-157, including immunogenicity for certain routes and difficulties with peptide impurities and active pharmaceutical ingredient characterization.

What the safety notice establishes

FDA describes limited or absent safety information for the proposed routes. This uncertainty should remain visible; it does not support reassuring claims about human use.

Avoid broad legal conclusions

The safety resource is not a substitute for checking the current, substance-specific compounding framework. A research label, clinical study registration, or supplier certificate does not establish product approval or clinical suitability.

Citations & Primary Documents

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
    U.S. Food and Drug Administration (2026).
    Primary Source Document

Related Compound Profiles